Benitec Biopharma Announces Updated Investor Webcast Information
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC)
October 14, 2024 6:05 AM EDTLeerink Partners analyst Mani Foroohar reiterated an Outperform rating and $13.00 price target on Benitec BioPharma (NASDAQ: BNTC).
The analyst comments "This morning, BNTC announced additional data from its Phase 1b/2a trial evaluating BB-301 in oculopharyngeal muscular dystrophy (OPMD) at the 29th Annual Congress of... More
